Biography for Nick Paul Taylor
Nick Taylor, UK Correspondent
Nick Taylor is a freelance journalist with more than six years' experience of reporting on the global biopharma industry. Since graduating with a biology degree from the University of York, Nick has written for numerous healthcare publications, including Nature BioPharma Dealmakers, Life Science Leader and Outsourcing-Pharma. You can contact him at email@example.com and follow him on Twitter at @NickPaulTaylor.
Articles by Nick Paul Taylor
A team at the University of California, San Diego (UCSD), has found biomarkers for ovarian tumors by mining two National Institutes of Health-sponsored databases. The bioinformatics-enabled research program has raised expectations that earlier diagnoses of ovarian cancer can be made, an advance that could improve outcomes in a tough therapeutic indication.
CRISPR Therapeutics has joined the hunt for bioinformatics talent. Fresh from a $64 million VC round, the CRISPR-Cas9 gene-editing startup is advertising for a head of bioinformatics, putting it in competition with multiple other biotechs that are trying to bolster their ranks of computational biologists.
The Cancer Prevention and Research Institute of Texas has given the University of Texas Southwestern Medical Center $5.6 million to build out its bioinformatics capabilities. Gaudenz Danuser, a professor UT Southwestern lured away from Harvard Medical School last year, is leading the initiative.
Genomics England has run into teething problems in the first few months of its massive genome sequencing initiative. About half of tumor samples sequenced to date have yielded substandard data, a shortcoming Genomics England is trying to overcome by trialing new processes and working with hospitals to incorporate the practices into their day-to-day tasks.
Trialbee has raised $5 million to expand its clinical trial recruitment business in the U.S.
Robert Gentleman has shared details of what he wants to achieve as 23andMe's VP of computational biology. And the ex-Genentech bioinformatics chief is looking to turn 23andMe's inexperience in drug discovery into a strength, notably by relying more on computational methods to generate data in early-stage tests.
Celgene has struck a deal with Cypher Genomics to boost its ability to find biomarkers. The agreement gives Celgene access to Cypher's Coral technology, a resource it thinks could help it identify the signatures of novel biomarkers in genomic data.
Hedge fund manager Kyle Bass has outlined how he picks pharma patents to challenge for his new money-spinning project. The project is underpinned by two emerging assets commonly thought of as a potential boon for drug developers: large data sets and algorithms with which to interrogate them.
PatientsLikeMe has lured Jason Johnson away from Merck. Johnson is leaving Merck after 14 years at the Big Pharma to head up R&D at PatientsLikeMe, a role which gives him responsibility for efforts to extract insights from patient-reported data.
Israel has become the latest country to disclose plans to create a population-scale database of linked genetic and clinical records. The current plan is reminiscent of the United Kingdom's 100,000 Genomes Project, with Israel considering working with tech firms to create a database of patients with rare genetic diseases.